RECQL1 and WRN Proteins Are Potential Therapeutic Targets in Head and Neck Squamous Cell Carcinoma
-
- Akihito Arai
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Tokuhiro Chano
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Kazunobu Futami
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Yasuhiro Furuichi
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Kaichiro Ikebuchi
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Takuma Inui
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Hitosuke Tameno
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Yasuko Ochi
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Taketoshi Shimada
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Yasuo Hisa
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
-
- Hidetoshi Okabe
- Authors' Affiliations: 1Department of Clinical Laboratory Medicine, Shiga University of Medical Science, Shiga; 2Department of Otolaryngology—Head and Neck Surgery, Kyoto Prefectural University of Medicine, Kyoto; and 3GeneCare Research Institute, Kanagawa, Japan
Description
<jats:title>Abstract</jats:title><jats:p>RECQL1 and WRN proteins are RecQ DNA helicases that participate in suppression of DNA hyper-recombination and repair. In this study, we report evidence supporting their candidacy as cancer therapeutic targets. In hypopharyngeal carcinomas, which have the worst prognosis among head and neck squamous cell carcinomas (HNSCC) that are rapidly rising in incidence, we found that RECQL1 and WRN proteins are highly expressed and that siRNA-mediated silencing of either gene suppressed carcinoma cell growth in vitro. Similarly, siRNA administration in a murine xenograft model of hypopharyngeal carcinoma markedly inhibited tumor growth. Moreover, combining either siRNA with cis-platinum (II) diammine dichloride significantly augmented the in vivo anticancer effects of this drug that is used commonly in HNSCC treatment. Notably, we observed no recurrence of some tumors following siRNA treatment in this model. Our findings offer a preclinical proof of concept for RECQL1 and WRN proteins as novel therapeutic targets to treat aggressive HNSCC and perhaps other cancers. Cancer Res; 71(13); 4598–607. ©2011 AACR.</jats:p>
Journal
-
- Cancer Research
-
Cancer Research 71 (13), 4598-4607, 2011-06-30
American Association for Cancer Research (AACR)
- Tweet
Details 詳細情報について
-
- CRID
- 1360004236366895744
-
- NII Article ID
- 10030463281
-
- ISSN
- 15387445
- 00085472
-
- Data Source
-
- Crossref
- CiNii Articles
- KAKEN